$XBI $94.52 | -5.94%
Covid Updates
$SRNE -7.2% Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Phase 2 Clinical Trial of COVI-MSC in COVID-19 Patients With Persistent Pulmonary Compromise After Recovery (Long-Hauler). source
$NRXP -8.3% NRx Pharmaceuticals Announces Expansion of ZYESAMI® (aviptadil) US Expanded Access and Right to Try Programs for Patients with COVID-19 Respiratory Failure who have Exhausted All Approved Treatments. source
$MOLN +2.8% Molecular Partners Finalizes License Agreement with Novartis for Ensovibep for COVID-19. source
Pipeline Updates
$IBRX -7.2% ImmunityBio Announces Results of Phase 2 Metastatic Pancreatic Cancer Trial at ASCO GI With Median Overall Survival of 6.3 Months in Patients With Third-Line Disease, More Than Doubling Historical Survival source
$EXEL -4.1% Exelixis Announces Detailed Results for Cabozantinib in Combination with Immunotherapies in Patients with Advanced Colorectal Cancer at ASCO GI 2022 source
$LPTX -4.2% Leap Therapeutics to Present Positive New Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ASCO GI Cancers Symposium source
$CRDF -10.5% Cardiff Oncology Announces New Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and Progression Free Survival source
$AZN +1.7% Imfinzi plus tremelimumab demonstrated unprecedented survival in 1st-line unresectable liver cancer with 31% of patients alive at three years source
$RVNC -6.8% Revance Receives Clarity on Path to Resubmission of the BLA for DaxibotulinumtoxinA for Injection Following Type A Meeting with FDA source
$GLPG -2.5% JYSELECA®▼ (FILGOTINIB) LICENSED FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN GREAT BRITAIN source
$CASI -6.1% CASI Pharmaceuticals Announces CNCT19 (CD19 CAR-T) Granted Orphan Drug Designation By The U.S. FDA source
$ATOS -4.8% Atossa Therapeutics Announces Advancement to Part B of Clinical Study of AT-H201. source
$RFL -5.6% Rafael Pharmaceuticals Announces Ongoing Successful Enrollment and Opening of Additional Sites for Phase 2 Clinical Trial of CPI-613® (Devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer. source
$IMAB -2.4% I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Toripalimab in Patients with Advanced Solid Tumors. source
$MBRX +1.2% Moleculin Announces Updated Preliminary Safety Data for Annamycin in Its Three Phase 1 Clinical Trials for Acute Myeloid Leukemia and Metastases of Soft Tissue Sarcoma. source
$VLON -9.5% Vallon Pharmaceuticals Presents New Data from Adult Stimulant Abuse Pattern Survey at the APSARD 2022 Annual Conference. source
$IMPL +1.0% Impel NeuroPharma Provides Updates on Trudhesa™ Launch and Recent Business Highlights. source
$OCUL -6.5% AffaMed Therapeutics, licensee of DEXTENZA® in Certain Asian Markets, Doses Their First Patient in Clinical Trial Evaluating the Safety and Efficacy of DEXTENZA® in China in Cataract Surgery Patients. source
$DYN -12.6% Dyne Therapeutics Announces FDA Clinical Hold on IND Application for DYNE-251 in Duchenne Muscular Dystrophy. source
$EVAX -2.4% Evaxion Biotech Receives Regulatory Clearance to Initiate Phase 2 Trial of EVX-01 in Combination with KEYTRUDA® for Treatment of Melanoma. source
$VERA -2.3% Vera Therapeutics Announces Phase 3 Clinical Trial for Atacicept in Lupus Nephritis. source
$BLRX +8.5% BioLineRx Announces Successful Completion of Pre-NDA Meeting with FDA for Motixafortide for Stem Cell Mobilization in Multiple Myeloma Patients. source
$ALKS -0.1% Alkermes to Present Data on Nemvaleukin Alfa at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. source
$SRRA -8.2% Sierra Oncology Updates Topline Data Timing for Pivotal Phase 3 Trial of Momelotinib in Myelofibrosis. source
$BLUE -9.4% bluebird Provides Update on FDA Review Timelines for Betibeglogene Autotemcel (beti-cel) for Beta-Thalassemia and Elivaldogene Autotemcel (eli-cel) for Cerebral Adrenoleukodystrophy (CALD). source
$CLNN -8.3% Clene Nanomedicine’s Second Asset, CNM-ZnAg, Completes 50% Patient Enrollment in COVID-19 Trial. source
$OSMT -1.8% RVL Pharmaceuticals to Host UPNEEQ® Overview and Business Update Webcast on January 19, 2022. source
$EGRX -2.3% Eagle Pharmaceuticals Announces Commercial Availability of Vasopressin. source
$ADCT -1.9% ADC Therapeutics Announces Exclusive License with Mitsubishi Tanabe Pharma Corporation to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Japan. source
$VACC +0.3% Cancer Research UK Dose First Patient in Phase I/IIa Trial of Lung Cancer Immunotherapy Vaccine. source
$IONS -9.0% Ionis' partner to evaluate tominersen for Huntington's disease in new Phase 2 trial. source
$EVLO -9.1% Evelo Biosciences Presents Data on EDP1815 Mechanism of Action and Supporting Ongoing Clinical Development for Inflammatory Diseases. source
Business Updates
$TPTX -5.6% Turning Point Therapeutics Provides Updates and Anticipated 2022 Clinical and Discovery Pipeline Milestones. source
$ENDP +2.1% Endo Reaches Agreement Intended to Settle Florida Governmental Opioid Cases and Claims. source
$ADMA -2.1% ADMA BioCenters Receives FDA Approval for its Fourth Plasma Collection Center Located in Goose Creek, SC. source
$XERS +1.4% Xeris Biopharma Reaffirms 2021 Guidance and Provides Business Update. source
$MTNB +1.3% Matinas BioPharma to Provide Corporate Update and 2022 Business Outlook on January 25, 2022. source
$ELYM +3.2% Eliem Therapeutics Provides Program Updates and an Overview of Expected Near-Term Milestones. source
$SDGR -6.2% Schrödinger Announces Acquisition of XTAL BioStructures, Inc.. source
$LTRN -9.2% Lantern Pharma Announces Collaboration & Research Agreement with The Danish Cancer Society Research Center to Support Clinical Development of Drug Candidates, LP-100 and LP-184, in Solid Tumors. source
Posted by FS/JM